NCATS, FDA meeting shines light on AAV manufacturing innovation
‘Doggybone DNA,’ high-density cultures and other AAV innovations among highlights
Technologies highlighted at a NCATS-FDA AAV manufacturing workshop could ramp up the production and durability of gene therapies, but questions remain about who will test drive these innovations and where the next wave of them will come from.
Relieving the manufacturing bottlenecks that limit the pace and scale of gene therapy development will require a step change in production efficiency (see “Mapping the Path to Gene Therapy 2.0”).
Innovation-focused panels at a Jan. 29 meeting on expanding AAV manufacturing capacity for rare disease